ARMO BioSciences, Inc. Common Stock
ARMO
ARMO was delisted on the 21st of June, 2018.
0 hedge funds and large institutions have $0 invested in ARMO BioSciences, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 63 closing their positions.
100% less funds holding
Funds holding: 65 → 0 (-65)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $509M → $0 (-$509M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 63
Top Buyers
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$154M |
| 2 |
AI
Alphabet Inc
Mountain View,
California
|
-$45.4M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$45.2M |
| 4 |
BlackRock
New York
|
-$30.8M |
| 5 |
HH
HSG Holding
Na,
Hong Kong
|
-$30.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$188K | -5,029 | Closed |
|
|
MLICM
52
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$174K | -4,662 | Closed |
|
|
AIG
53
American International Group
New York
| – | -$164K | -4,377 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$78K | -2,079 | Closed |
|
|
SO
55
STRS Ohio
Columbus,
Ohio
| – | -$71K | -1,900 | Closed |
|
56
Barclays
London,
United Kingdom
| – | -$53K | -1,416 | Closed |
|
57
BNP Paribas Financial Markets
Paris,
France
| – | -$47.5K | -1,269 | Closed |
|
58
Legal & General Group
London,
United Kingdom
| – | -$45K | -1,208 | Closed |
|
59
Bank of America
Charlotte,
North Carolina
| – | -$39K | -1,047 | Closed |
|
60
Citigroup
New York
| – | -$22K | -586 | Closed |
|
|
AIP
61
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$22K | -578 | Closed |
|
|
CCA
62
Catalyst Capital Advisors
Huntington,
New York
| – | -$7K | -178 | Closed |
|
63
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$6K | -150 | Closed |
|
ARMO Hedge Fund Activity: Q2 2018 in Review
0 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ARMO BioSciences, Inc. Common Stock (ARMO) for Q2 2018, worth a combined $0 — down 100% from $509M a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of ARMO and 0 opened new positions — a net loss of 63 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was OrbiMed, exiting entirely with an estimated $154M sold.
- 0 institutional investors held ARMO BioSciences, Inc. Common Stock (ARMO) as of Q2 2018, down from 65 in Q1 2018.
- Funds reported $0 of ARMO BioSciences, Inc. Common Stock stock for Q2 2018, down 100% quarter-over-quarter.
- 0 funds opened new ARMO BioSciences, Inc. Common Stock positions in Q2 2018 and 63 closed out, a net change of -63 holders.
- The largest ARMO BioSciences, Inc. Common Stock seller in Q2 2018 was OrbiMed, an estimated $154M sold.
Based on aggregated 13F filings for Q2 2018.